Durect (NASDAQ:DRRX) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald.
Ekso Bionics Holdings (NASDAQ:EKSO) initiated with Overweight rating and $1 (79% upside) price target at Cantor. Shares up 6% premarket.
Kadmon Holdings (NYSE:KDMN) initiated with Overweight rating and $8 (223% upside) price target at Cantor.
Regulus Therapeutics (NASDAQ:RGLS) initiated with Buy rating and $2 (233% upside) price target at H.C. Wainwright.
Corcept Therapeutics (NASDAQ:CORT) initiated with Buy rating and $18 (43% upside) price target at H.C. Wainwright.
Encompass Health (NYSE:EHC) upgraded to Buy with a $73 (20% upside) price target at BofA Merrill Lynch.
Aclaris Therapeutics (NASDAQ:ACRS) downgraded to Market Perform at JMP Securities.
MEDNAX (NYSE:MD) downgraded to Underperform with a $9 (59% downside risk) price target at BofA Merrill Lynch.
Zafgen (NASDAQ:ZFGN) downgraded to Neutral with a $0.78 (11% upside) price target at Wedbush.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.